Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1885)	8/23/2000 9:32:15 AM
From: nigel bates	Respond to of 4974

Aug. 23, 2000--Gemini Genomics plc (NASDAQ: GMNI - news) today announced that the underwriters of its IPO, SG Cowen Securities Corporation and Chase Hambrecht & Quist have exercised their option to purchase all additional shares set aside by Gemini (``green shoe option'') to cover over-allotments in connection with the initial public offering. Dr. Paul Kelly, president and chief executive officer of Gemini said, ``Our IPO raised over $84 million and the 'green shoe' will provide an additional $12.6 million. We are very excited with the market's enthusiastic reception of our company and its leading position in the growing genomics marketplace.'' Gemini is a clinical genomics company that identifies the relationships between human genes and human health and disease. Gemini collects clinical and medical information from human volunteers from a number of different groups such as twins, disease affected individuals and founder type populations and uses this data to identify genes relevant to disease. Discoveries from this research will be licensed to pharmaceutical, biotechnology and other companies engaged in drug discovery and or gene-based diagnostic applications. Gemini is headquartered in Cambridge England with further facilities in Uppsala, Sweden and Boston, Massachusetts USA.